Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Winter Games
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

FDA won't consider a new mRNA vaccine for flu

Digest more
Top News
Overview
 · 14h · on MSN
Moderna says FDA refuses to review its application for experimental flu shot
The Food and Drug Administration has refused to start a review of Moderna's application for its experimental flu shot, the company said.

Continue reading

Opinion
 · 4h
Moderna Has a Promising New Flu mRNA Vaccine. Trump’s FDA Wants Nothing to Do With It
 · 1d · on MSN
FDA won’t review Moderna application for first mRNA-based flu vaccine
 · 17h
F.D.A. Refuses to Review Moderna Flu Vaccine
The vaccine maker Moderna said on Tuesday that the Food and Drug Administration had notified the company that the agency would not review its mRNA flu vaccine, the latest sign of federal health policy...

Continue reading

 · 1d
FDA refuses to review Moderna’s application for mRNA flu vaccine, company says
 · 1d
FDA Refuses to Consider Approving Use of Moderna’s New Flu Vaccine
16h

Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna
Seeking Alpha
5mon

Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of ...
The National Law Review
6mon

Moderna Announces Data to be Presented at ESMO Congress 2025

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO ...
  • Privacy
  • Terms